Nektar Therapeutics (NKTR) Shares Bought by California State Teachers Retirement System

Share on StockTwits

California State Teachers Retirement System lifted its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 256,624 shares of the biopharmaceutical company’s stock after buying an additional 6,879 shares during the period. California State Teachers Retirement System owned about 0.15% of Nektar Therapeutics worth $8,435,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NKTR. Flinton Capital Management LLC increased its holdings in Nektar Therapeutics by 23.5% in the fourth quarter. Flinton Capital Management LLC now owns 69,360 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 13,216 shares during the period. Dimensional Fund Advisors LP boosted its position in Nektar Therapeutics by 82.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 408,526 shares of the biopharmaceutical company’s stock valued at $13,433,000 after acquiring an additional 184,055 shares during the last quarter. United Services Automobile Association boosted its position in Nektar Therapeutics by 13.9% during the fourth quarter. United Services Automobile Association now owns 63,696 shares of the biopharmaceutical company’s stock valued at $2,094,000 after acquiring an additional 7,751 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in Nektar Therapeutics by 1.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 82,254 shares of the biopharmaceutical company’s stock valued at $2,559,000 after acquiring an additional 883 shares during the last quarter. Finally, Employees Retirement System of Texas boosted its position in Nektar Therapeutics by 163.6% during the fourth quarter. Employees Retirement System of Texas now owns 29,000 shares of the biopharmaceutical company’s stock valued at $953,000 after acquiring an additional 18,000 shares during the last quarter. Institutional investors own 93.35% of the company’s stock.

NKTR has been the topic of a number of research analyst reports. Mizuho reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Goldman Sachs Group initiated coverage on shares of Nektar Therapeutics in a research report on Thursday, December 13th. They set a “buy” rating and a $62.00 price target on the stock. BidaskClub raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. HC Wainwright reaffirmed a “hold” rating and set a $47.00 price target on shares of Nektar Therapeutics in a research report on Monday, March 4th. Finally, Piper Jaffray Companies set a $100.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and a consensus price target of $73.92.

NKTR stock opened at $33.48 on Friday. The stock has a market cap of $5.99 billion, a PE ratio of 8.86 and a beta of 3.09. The company has a current ratio of 17.53, a quick ratio of 17.39 and a debt-to-equity ratio of 0.14. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $108.23.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. During the same quarter in the previous year, the firm posted ($0.21) EPS. As a group, sell-side analysts expect that Nektar Therapeutics will post -3.02 EPS for the current fiscal year.

In other news, SVP Jillian B. Thomsen sold 16,119 shares of the stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $42.16, for a total transaction of $679,577.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Maninder Hora sold 2,386 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $101,142.54. Following the transaction, the senior vice president now directly owns 99,374 shares in the company, valued at approximately $4,212,463.86. The disclosure for this sale can be found here. Insiders have sold a total of 241,824 shares of company stock worth $10,249,993 in the last three months. Insiders own 4.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Shares Bought by California State Teachers Retirement System” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4239826/nektar-therapeutics-nktr-shares-bought-by-california-state-teachers-retirement-system.html.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Further Reading: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nordea Investment Management AB Decreases Holdings in LKQ Co.
Nordea Investment Management AB Decreases Holdings in LKQ Co.
Nordea Investment Management AB Lowers Position in AutoZone, Inc.
Nordea Investment Management AB Lowers Position in AutoZone, Inc.
Redmile Group LLC Sells 2,034 Shares of LHC Group, Inc.
Redmile Group LLC Sells 2,034 Shares of LHC Group, Inc.
Redmile Group LLC Acquires 2,179,160 Shares of ImmunoGen, Inc.
Redmile Group LLC Acquires 2,179,160 Shares of ImmunoGen, Inc.
F.N.B. Corp  Given Average Recommendation of “Hold” by Brokerages
F.N.B. Corp Given Average Recommendation of “Hold” by Brokerages
Insider Buying: Total Energy Services Inc  Insider Purchases 4,000 Shares of Stock
Insider Buying: Total Energy Services Inc Insider Purchases 4,000 Shares of Stock


© 2006-2019 Ticker Report